{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:13:48Z","timestamp":1782260028872,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["contemporaryclinicaltrials.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.cct.2015.05.012","type":"journal-article","created":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T06:47:33Z","timestamp":1432190853000},"page":"129-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention"],"prefix":"10.1016","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct02334254","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Fei","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2015.05.012_bb0005","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur. Heart J."},{"issue":"23","key":"10.1016\/j.cct.2015.05.012_bb0010","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1161\/CIR.0000000000000041","article-title":"2014 AHA\/ACC\/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cct.2015.05.012_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH09-08-0580","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary intervention\/stenting","volume":"103","author":"Lip","year":"2010","journal-title":"Thromb. Haemost."},{"issue":"37","key":"10.1016\/j.cct.2015.05.012_bb0020","first-page":"2541","article-title":"European Society of Cardiology working group on thrombosis. 2014 ESC\/EACTS Guidelines on myocardial revascularization","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.cct.2015.05.012_bb0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2010.11.019","article-title":"Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation","volume":"148","author":"Gao","year":"2011","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.cct.2015.05.012_bb0030","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1253\/circj.CJ-09-0880","article-title":"Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation","volume":"74","author":"Gao","year":"2010","journal-title":"Circ. J."},{"key":"10.1016\/j.cct.2015.05.012_bb0035","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1378\/chest.08-0350","article-title":"Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting","volume":"134","author":"Manzano-Fern\u00e1ndez","year":"2008","journal-title":"Chest"},{"issue":"9872","key":"10.1016\/j.cct.2015.05.012_bb0040","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"WOEST study investigators. WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2015.05.012_bb0045","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE-W): a randomized controlled trial","volume":"367","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2015.05.012_bb0050","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1160\/TH09-08-0563","article-title":"Contra: \u201canti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation\u201d","volume":"102","author":"Apostolakis","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cct.2015.05.012_bb0055","doi-asserted-by":"crossref","first-page":"204S","DOI":"10.1378\/chest.126.3_suppl.204S","article-title":"The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy","volume":"126","author":"Ansell","year":"2004","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.cct.2015.05.012_bb0060","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ahj.2014.06.014","article-title":"Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?","volume":"168","author":"Huber","year":"2014","journal-title":"Am. Heart J."},{"issue":"5","key":"10.1016\/j.cct.2015.05.012_bb0065","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cct.2015.05.012_bb0070","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2015.05.012_bb0075","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2015.05.012_bb0080","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2015.05.012_bb0085","author":"Bayer Pharma"},{"key":"10.1016\/j.cct.2015.05.012_bb0090","author":"Janssen Pharmaceuticals Inc."},{"issue":"1","key":"10.1016\/j.cct.2015.05.012_bb0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.cct.2015.05.012_bb0100","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jcin.2014.06.014","article-title":"Direct oral anticoagulants: new drugs and new concepts","volume":"7","author":"Levy","year":"2014","journal-title":"JACC Cardiovasc. Interv."},{"issue":"11","key":"10.1016\/j.cct.2015.05.012_bb0105","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.cct.2015.05.012_bb0110","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1161\/CIRCULATIONAHA.113.002589","article-title":"Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial","volume":"128","author":"Steg","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.cct.2015.05.012_bb0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.thromres.2014.05.006","article-title":"Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting","volume":"134","author":"Stimpfle","year":"2014","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.cct.2015.05.012_bb0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11739-013-1000-4","article-title":"Proton pump inhibitors and clopidogrel: an association to avoid?","volume":"9","author":"D'Ugo","year":"2014","journal-title":"Intern. Emerg. Med."},{"issue":"2","key":"10.1016\/j.cct.2015.05.012_bb0125","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/j.thromres.2013.06.015","article-title":"Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays","volume":"132","author":"Tsantes","year":"2013","journal-title":"Thromb. Res."},{"key":"10.1016\/j.cct.2015.05.012_bb0130","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.cct.2015.05.012_bb0135","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","article-title":"Stent thrombosis in randomized clinical trials of drug-eluting stents","volume":"356","author":"Mauri","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cct.2015.05.012_bb0140","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.cjca.2012.06.012","article-title":"Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention\/stenting: a systematic review and meta-analysis","volume":"29","author":"Andrade","year":"2013","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.cct.2015.05.012_bb0145","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacc.2007.11.035","article-title":"Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis","volume":"51","author":"Ruiz-Nodar","year":"2008","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714415300112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714415300112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T09:58:44Z","timestamp":1531735124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714415300112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":29,"alternative-id":["S1551714415300112"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2015.05.012","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2015.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}